Hemispherx Biopharma Enters into Alfa-n3 Interferon Clinical Trial, Sales, Marketing, Distribution, and Supply Agreement with Saudi Arabia’s Premier Pharma Company in Fight Against the Deadly MERS Disease

by Barry101 | Apr 4, 2016 | Press Release

PHILADELPHIA, April 04, 2016 — Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the Company) announced today that it has entered into a Clinical Trial, Sales, Marketing, Distribution, and Supply Agreement with Scientific Products Pharmaceutical Co. LTD (SCIEN) located...

Hemispherx Biopharma Announces Financial Results for the Year Ended December 31, 2015

by Barry101 | Mar 29, 2016 | Press Release

Hemispherx Biopharma Management Team: Reflects Company’s Aggressive Commitment to Strategies Designed to Reach Commercial Goals, Preserve Financial Capital, and Increase Stockholder ValueConference Call Scheduled for Wednesday, March 30th at 2 PM...

Hemispherx Biopharma Announces Conference Call to Discuss Management Changes and Provide Corporate Update on March 30, 2016

by Barry101 | Mar 22, 2016 | Press Release

Philadelphia, PA, Tuesday, March 22, 2016: Hemispherx Biopharma, Inc. (NYSE MKT: HEB) (the “Company” or “Hemispherx”) announced today that it anticipates releasing its 2015 year-end financial results on Tuesday, March 29, 2016. Hemispherx will...

Hemispherx Biopharma Reviews Ampligen® Data with National Institute of Neurological Disorders and Stroke (NINDS)

by Barry101 | Mar 10, 2016 | Press Release

National Institutes of Health Research Focus on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is Set to be a Game Changer for PatientsPhiladelphia, PA, Thursday, March 10, 2016: Hemispherx Biopharma (NYSE MKT:HEB) (the “Company” or...

Hemispherx Biopharma Management Team: Reflects Company's Aggressive Commitment to Strategies Designed to Reach Commercial Goals, Preserve Financial Capital, and Increase Stockholder Value

by Barry101 | Feb 22, 2016 | Press Release

Philadelphia, PA, Monday, February 22, 2016: Hemispherx Biopharma, Inc. (NYSE MKT: HEB) (the “Company” or “Hemispherx”) has announced that the Board of Directors has made several changes to its executive management team, in light of the...

Hemispherx Biopharma Exploring Possible Research Programs in Zika Virus Modeled on a Prior Alferon® N Clinical Trial on Closely Related Flavivirus (West Nile)

by Barry101 | Feb 9, 2016 | Press Release

Both Viruses Transmitted by Identical Mosquito FamilyPhiladelphia, PA, Tuesday, February 09, 2016: Hemispherx Biopharma, Inc. (NYSE MKT: HEB) announced today that it is beginning to consider study designs for potential tests of the activity and potential uses of its...